Navigation Links
Rush researchers studying stem cell therapy to repair damaged knee cartilage
Date:1/24/2013

(CHICAGO) Rush University Medical Center is conducting the nation's first clinical study of an innovative stem cell drug, Cartistem, to repair knee cartilage damaged by aging, trauma or degenerative diseases such as osteoarthritis.

Cartistem is manufactured from mesenchymal stem cells derived from allogeneic (donor) umbilical cord blood. Umbilical cord blood is a readily accessible source of high-quality stem cells, is associated with minimal health risks and carries relatively few ethical concerns.

The stem cells are mixed with hyaluronan, a natural polymer that plays a major role in wound healing and is a building block of joint cartilage. Cartistem is surgically administered into the area of cartilage damage following an arthroscopic surgery as an adjunct to microfracture, a commonly used technique used to repair cartilage damage.

The principal investigator on the study is Dr. Brian Cole, a professor in the department of orthopedics and anatomy and cell biology at Rush University Medical Center. Dr. Cole is the head of Rush's Cartilage Restoration Center and is also the head team physician for the Chicago Bulls. Cole and his co-researchers will assess the drug's safety as well as its ability to regenerate cartilage repair tissue and reduce pain in patients with localized cartilage loss in the knee.

Treating cartilage damage can be problematic because the tissue does not contain blood vessels or nerves and therefore has a limited ability to re-grow. Various treatments for cartilage degeneration, such as drug therapy, arthroscopy and joint replacement, yield mixed results and are unable to regenerate damaged tissue.

"Finding a biological solution for cartilage regeneration in orthopedics is one of the fastest growing areas of research and development in our specialty, said Cole. "Rush is spearheading this field of research with the ultimate goal of safely improving outcomes and sparing patients from having more complicated surgery at a relatively young age."

The two-year, phase I/IIa study will enroll a total of 12 participants aged 18 years and older, with a body mass index of less than 35. Initially, six individuals with lesions sized 2 to 5 centimeters will be recruited into the study; an additional six volunteers with lesions larger than 5 centimeters will be enrolled sequentially. Each participant will undergo eligibility screening followed by a 12-month observation period to determine the safety and efficacy of the drug with an additional long-term follow-up evaluation at 24 months.

"With a burgeoning aging, yet active population, our patients are looking for effective non-joint replacement solutions to treat their damaged knee cartilage," said Cole. "This research is significant in that it utilizes a commonly performed operation (microfracture) in an effort to improve upon variable outcomes."

"Notably, this is a treatment for patients with localized cartilage damage and not for patients who are diagnosed with diffuse or bone on bone arthritis who have otherwise been told they require a knee replacement." said Cole.


'/>"/>

Contact: Deb Song
deb_song@rush.edu
312-942-0588
Rush University Medical Center
Source:Eurekalert

Related medicine news :

1. Researchers discover new mutations driving malignant melanoma
2. CDC Researchers Spot Increase in New Stomach Bug Strain
3. Researchers prevent cancer spread by blocking tissue scarring
4. Researchers uncover genes role in rheumatoid arthritis, findings pave way for new treatments
5. New drug improves survival in multiple myeloma relapse, Moffitt Cancer Center researchers say
6. Researchers discover promising prognostic marker for aggressive breast cancer
7. Researchers design a new imaging technique for identifying the age and sex of a corpse
8. Researchers map emotional intelligence in the brain
9. Researchers find that simple blood test can help identify trauma patients at greatest risk of death
10. Mayo Clinic researchers identify enzyme involved in deadly brain tumors
11. UNC researchers use luminescent mice to track cancer and aging in real-time
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... January 23, 2017 , ... Old School Labs™, makers of the wildly popular ... bodybuilder Breon Ansley to its growing team of brand ambassadors. The Olympia top finisher ... in less than a year was able to turn professional, participating in the 2013 ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... programs and resources at seafoodnutrition.org/programs and seafoodnutrition.org/resources to assist in teaching communities ... These resources have been developed for use by nutrition educators and influencers ...
(Date:1/22/2017)... ... January 22, 2017 , ... Zifam Pinnacle, an Australian company dedicated ... met with big-name retail buyers at the January ECRM Trade Show in Hilton Head, ... the utmost safety standards in all of its creations to help create a more ...
(Date:1/21/2017)... ... January 21, 2017 , ... "ProDOF is the perfect set of tools for video ... subject in a scene," said Christina Austin - CEO of Pixel Film Studios. , ... Easily create the illusion of a DSLR racking focus from one area into the next. ...
(Date:1/21/2017)... ... 21, 2017 , ... Santa Rosa Orthopaedics (SRO) is excited ... 167 Lynch Creek Way. The Petaluma office features three comfortable patient exam rooms, ... services and on-site x-ray services. Two multi-specialist orthopaedic surgeons Dr. Neema Pourtaheri ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... 2017 Longer life expectancy and rising healthcare expenditure ... for medical device technologies. BCC Research reveals in its new ... region, should see strong growth due to rising government healthcare ... Continue Reading ... ...
(Date:1/23/2017)... -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: ... agreement with the Children,s Hospital of Philadelphia ... US key opinion leader in the mitochondrial medicine field. ... Dr. ... research program, NVP015, in certain experimental disease models. The research ...
(Date:1/21/2017)... -- ResMed (NYSE: RMD ), BMC ( Beijing, ... ) today announced they have agreed on a global settlement ... permitted to sell their existing products in exchange for royalty payments ... 3B to close the Florida litigation between ... liability or wrongdoing by any party. The five-year ...
Breaking Medicine Technology: